SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sequent Scientific - Quaterly Results

13 Feb 2024 Evaluate
The sales is pegged at Rs. 422.05 millions for the December 2023 quarter. The mentioned figure indicates decline with the sales recorded at Rs. 569.99 millions during the year-ago period.The Total Profit for the quarter ended December 2023 of Rs. 45.80 millions grew from Rs.-12.25 millions Operating profit Margin for the quarter ended December 2023 improved to 92.88% as compared to -11.23% of corresponding quarter ended December 2022


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202312 202212 % Var 202312 202212 % Var 202303 202203 % Var
Sales 422.05 569.99 -25.95 1317.47 1760.90 -25.18 2226.85 2196.26 1.39
Other Income 134.44 76.23 76.36 330.05 202.29 63.16 282.42 276.43 2.17
PBIDT 92.88 -11.23 -927.07 120.82 -0.86 -14148.84 18.82 268.93 -93.00
Interest 11.45 7.17 59.69 33.36 16.46 102.67 25.13 16.10 56.09
PBDT 81.43 -18.40 -542.55 24.92 -17.32 -243.88 -6.31 252.83 -102.50
Depreciation 20.53 21.54 -4.69 68.31 67.84 0.69 91.15 95.93 -4.98
PBT 60.90 -39.94 -252.48 -43.39 -85.16 -49.05 -97.46 156.90 -162.12
TAX 15.10 -27.69 -154.53 -11.98 -40.81 -70.64 -36.66 8.91 -511.45
Deferred Tax 10.51 -13.98 -175.18 -16.57 -14.83 11.73 -30.94 5.20 -695.00
PAT 45.80 -12.25 -473.88 -31.41 -44.35 -29.18 -60.80 147.99 -141.08
Equity 498.86 498.86 0.00 498.87 498.87 0.00 498.87 496.74 0.43
PBIDTM(%) 22.01 -1.97 -1216.99 9.17 -0.05 -18892.21 0.85 12.24 -93.10

Viyash Scientific Share Price

209.75 1.40 (0.67%)
22-Apr-2026 10:45 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1653.40
Dr. Reddys Lab 1215.55
Cipla 1228.55
Zydus Lifesciences 926.50
Lupin 2307.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×